The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 08, 2012
Filed:
Aug. 07, 2008
Tianbao LU, Churchville, PA (US);
Richard Alexander, Newark, DE (US);
Richard W. Connors, Harleysville, PA (US);
Maxwell D. Cummings, Wayne, PA (US);
Robert A. Galemmo, Paoli, PA (US);
Heather Rae Hufnagel, Glenmoore, PA (US);
Dana L. Johnson, Upper Black Eddy, PA (US);
Ehab Khalil, West Chester, PA (US);
Kristi A. Leonard, Flourtown, PA (US);
Thomas P. Markotan, Morgantown, PA (US);
Anna C. Maroney, Media, PA (US);
Jan L. Sechler, Doylestown, PA (US);
Jeremy M. Travins, Downingtown, PA (US);
Robert W. Tuman, Chalfont, PA (US);
Tianbao Lu, Churchville, PA (US);
Richard Alexander, Newark, DE (US);
Richard W. Connors, Harleysville, PA (US);
Maxwell D. Cummings, Wayne, PA (US);
Robert A. Galemmo, Paoli, PA (US);
Heather Rae Hufnagel, Glenmoore, PA (US);
Dana L. Johnson, Upper Black Eddy, PA (US);
Ehab Khalil, West Chester, PA (US);
Kristi A. Leonard, Flourtown, PA (US);
Thomas P. Markotan, Morgantown, PA (US);
Anna C. Maroney, Media, PA (US);
Jan L. Sechler, Doylestown, PA (US);
Jeremy M. Travins, Downingtown, PA (US);
Robert W. Tuman, Chalfont, PA (US);
Janssen Pharmaceutica N.V., Beerse, BE;
Abstract
The invention is directed to triazolopyridazine compounds of Formula I: where R, R, R, R, R, and A are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of c-Met, and the use of such compounds to reduce or inhibit kinase activity of c-Met in a cell or a subject, and modulate c-Met expression in a cell or subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to c-Met. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.